X4 Pharmaceuticals Ownership
| XFOR Stock | USD 0.39 0.04 11.43% |
Shares in Circulation | First Issued 2016-12-31 | Previous Quarter 200.8 M | Current Value 200.9 M | Avarage Shares Outstanding 57.1 M | Quarterly Volatility 74.5 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
XFOR |
XFOR Stock Ownership Analysis
About 68.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 1.01. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. X4 Pharmaceuticals recorded a loss per share of 0.08. The entity last dividend was issued on the 14th of March 2019. The firm had 1:6 split on the 14th of March 2019. X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. The company was founded in 2010 and is headquartered in Boston, Massachusetts. X4 Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 83 people. For more information please call Paula Ragan at 857 529 8300 or visit https://www.x4pharma.com.Besides selling stocks to institutional investors, X4 Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different X4 Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align X4 Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
X4 Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Only 1.14% of X4 Pharmaceuticals are currently held by insiders. Unlike X4 Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against X4 Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of X4 Pharmaceuticals' insider trades
XFOR Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as X4 Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading X4 Pharmaceuticals backward and forwards among themselves. X4 Pharmaceuticals' institutional investor refers to the entity that pools money to purchase X4 Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2024-06-30 | 2.8 M | Ensign Peak Advisors Inc | 2024-09-30 | 2.5 M | Schonfeld Strategic Advisors Llc | 2024-09-30 | 1.9 M | Ubs O'connor Llc | 2024-09-30 | 1.5 M | Northern Trust Corp | 2024-09-30 | 1.3 M | Sio Capital Management, Llc | 2024-09-30 | 1.3 M | Parkman Healthcare Partners Llc | 2024-06-30 | 806.6 K | Velan Capital Investment Management Lp | 2024-06-30 | 659 K | Point72 Asset Management, L.p. | 2024-09-30 | 625.1 K | Bain Capital Life Sciences Investors, Llc | 2024-09-30 | 16.9 M | Nea Management Company, Llc | 2024-06-30 | 15 M |
X4 Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific X4 Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on X4 Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases X4 Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
X4 Pharmaceuticals Outstanding Bonds
X4 Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. X4 Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most XFOR bonds can be classified according to their maturity, which is the date when X4 Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| XEROX HLDGS P Corp BondUS98421MAB28 | View | |
| XEROX HLDGS P Corp BondUS98421MAA45 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| US98420EAB11 Corp BondUS98420EAB11 | View |
Pair Trading with X4 Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if X4 Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in X4 Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with XFOR Stock
| 0.75 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.7 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.83 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against XFOR Stock
| 0.81 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.67 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.5 | ESLAW | Estrella Immunopharma | PairCorr |
| 0.45 | PHVS | Pharvaris BV | PairCorr |
| 0.38 | PMVP | Pmv Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to X4 Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace X4 Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back X4 Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling X4 Pharmaceuticals to buy it.
The correlation of X4 Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as X4 Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if X4 Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for X4 Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for XFOR Stock Analysis
When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.